---
schema_version: "secwatch.filing_event.v1"
accession: "0001818382-23-000028"
form_type: "8-K"
ticker: "HUMA"
cik: "0001818382"
company_name: "Humacyte, Inc."
filed_at: "2023-05-12T23:59:59+00:00"
generated_at: "2026-06-15T02:43:52.204563+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Humacyte Q1 net loss $37M; secures second RMAT for HAV in vascular trauma, plans BLA filing in 2023

## Summary
- Net loss of $37.0M in Q1 2023 vs $19.8M in Q1 2022; cash & investments $131.7M at March 31, 2023.
- Received second FDA RMAT designation for HAV in urgent arterial repair after extremity vascular trauma.
- Completed enrollment in Phase 3 hemodialysis access trial (240 patients); top-line results expected in 2024.
- Plans to file BLA with FDA later in 2023 for HAV in vascular trauma; V005 trial enrolled 66 patients.
- Subsequent to Q1, secured up to $160M funding arrangement with Oberland Capital to fund operations past potential approval.

## SEC filing metadata
- accession: 0001818382-23-000028
- form_type: 8-K
- ticker: HUMA
- cik: 0001818382
- company_name: Humacyte, Inc.
- filed_at: 2023-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818382/000181838223000028/0001818382-23-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818382/000181838223000028/huma-20230512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818382-23-000028
- JSON: https://secwatch.observer/filing/0001818382-23-000028.json
- Plain text: https://secwatch.observer/filing/0001818382-23-000028.txt

## Key facts
- Earnings Releases
  Humacyte, Inc. reported the first quarter of 2023 results: net income $37.0 million.
  - Period: the first quarter of 2023
  - Net income: $37.0 million
  - Result: reported results
  source text: Net loss was $37.0 million for the first quarter of 2023, compared to $19.8 million for the first quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818382/000181838223000028/0001818382-23-000028-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.